. 2017 Jul 10;49(4):442–454. doi: 10.1007/s12029-017-9983-0

Table 1.

Characteristics of included studies

First author [ref]		Location, setting	Study design	Total number of patients	Primary outcome of interest	Patient on statins		Patient not on statins		Variables adjusted for	Newcastle-Ottawa score
First author [ref]		Location, setting	Study design	Total number of patients	Primary outcome of interest	No. of EAC/EC cases	No. of non-EAC/EC cases	No. of EAC/EC cases	No. of non-EAC/EC cases	Variables adjusted for	Newcastle-Ottawa score
Nguyen 2010 [14]		US; multicentre, hospital-based	Retrospective cohort	344 patients OAC 33	Incidence of OAC in Barrett’s cohort	6	63	27	188	1, 2, 7, 9	8^a
Nguyen 2009 [15]		US; multicentre, hospital-based	Nested case control	812 patients OAC 116, BO 696	Incidence of OAC in Barrett’s cohort	41	336	75	360	1, 2, 3	9^a
Kastelein [16]		The Netherlands; multicentre, hospital-based	Prospective cohort	570 patients HGD/OAC 38	Incidence of OACC in Barrett’s cohort	9	200	29	332	1, 2, 7, 8, 9	9^a
Kantor [17]		US; hospital-based	Prospective cohort	411 patients OAC 56	Incidence of OAC in Barrett’s cohort	6	50	50	305	1, 2, 4, 9	9^a
Beales 2012a [18]		UK; hospital-based	Case control	255 patients OAC 85, BO 170	Incidence of OAC in Barrett’s cohort	17	60	68	110	1, 2, 4, 5, 6, 8	8^a
Krishnamoorthi [19]		US; population-based	Cohort	9660 patients OAC 103	Incidence of OAC in Barrett’s cohort	NR	NR	NR	NR	1, 2, 4, 6, 9	8^a
Iyer [20]		UK; population-based	Cohort	NR	Incidence of OAC in Barrett’s cohort	NR	NR	NR	NR	NR	6^a
Agrawal [21]		US; hospital-based	Case control	583 patients	Incidence of OAC in Barrett’s cohort	55	307	60	161	1, 4, 5, 6, 9	7^a
Masclee [22]		UK and the Netherlands; multicentre, population-based	Nested case control	777 patients OAC 45, BO 732	Incidence of OAC in Barrett’s cohort	12	253	33	479	None listed	7^a
Cooper [23]		UK; population-based	Nested case control	3749 patients OAC 55	Incidence of OAC in Barrett’s cohort	18	1124	37	2570	1, 2, 4	8^a
Nguyen 2015 [24]		US; population-based	Nested case control	1167 patients OAC 311, BO 856	Incidence of OAC in Barrett’s cohort	125	462	186	394	1, 4, 6, 9	9^a
Kaye [25]		UK; population-based	Case control	530 patients OC 100, control 430	Incidence of any OC in population	9	34	91	396	1, 2, 4, 6	8^a
Friedman [26]		US; population-based	Cohort	4,413,100 patients	Incidence of any OC in population	68	762	361,802	4,050,468	NR	9^a
Hippiseley-Cox [27]	Male	UK; population-based	Cohort	989,729, OC 1225	Incidence of any OC in population	216	120,866	1009	867,638	1, 4, 6	9^a
Hippiseley-Cox [27]	Female	UK; population-based	Cohort	1,013,565, OC 584	Incidence of any OC in population	78	104,670	506	908,311	1, 4, 6	9^a
Vinogradava [28]		UK; population-based	Nested case control	16,200 patients OC 3159, control 13,041	Incidence of any OC in population	496	2106	2663	10,935	4, 6	9^a
Bhutta [29] (abstract)		UK; population-based	Prospective cohort	18,484 patients OAC 581, OSC 322	Incidence of any OC in population	615	2539	3101	12,229	NR	7^a
Lai [30]		Taiwan; population-based	Case control	2745 patients OC 549, control 2196	Incidence of any OC in population	49	238	500	1958	1, 2, 8, 9	6^a
Chan [31]		Taiwan; population-based	Case control	985 patients OC 197, control 788	Incidence of any OC in population	29	131	168	657	8, 9	7^a
Alexandre [32]	EAC	UK; population-based	Nested case control	OAC 581 Control 2167	Incidence of OAC in population	60	222	521	1945	4, 6, 9	8^a
Alexandre [32]	EGJA	UK; population-based	Nested case control	OAC 213 Control 783	Incidence of OAC in population	20	79	193	704	4, 6, 9	8^a
Beales 2012b [33]		UK; hospital-based	Case control	560 patients OAC 112, control 448	Incidence of OAC in population	19	158	93	290	1, 2, 4, 5, 6, 9	8^a

Variables adjusted for (1) age, (2) sex, (3) race, (4) smoking, (5) alcohol use, (6) obesity, (7) BO length, (8) oesophagitis or reflux symptoms, (9) medications (NSAIDs/aspirin)

NR not reported

^aStatin use at baseline and not during course of study